reference/16780398

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16780398

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	1446
issn	1078-0432 1557-3265
issueIdentifier	5
pageRange	1435-1446
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	1435
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577
bibliographicCitation	Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01;18(5):1435–46. PMID: 22261807; PMCID: PMC6167936.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc35be4c1b5944456db905401b89f5ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_030cfd28c5364d3f3a948ba37d1b8eec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f81dbaea8ba7d10c130fc599a6b3d70a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_863c48ea4cdf7e4665c83b9eedaa5806 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e8965cfd59e62a48c9efd98c11615ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90cbb8281c670c38495ca89299c2d5b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e04b99bace2320a44d53a3426ccd1813 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e53aa58040fea989b9ea66437e693b3c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27076db0d48020a58c331a8b06eae025 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86a6acc0feeee1a816765b6d6b780bf1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61f6121048e5fd373c7eec1bc0afcdfb
date	2012-03-01^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/22261807 https://pubmed.ncbi.nlm.nih.gov/PMC6167936 https://doi.org/10.1158/1078-0432.ccr-11-1951
isPartOf	https://portal.issn.org/resource/ISSN/1557-3265 https://portal.issn.org/resource/ISSN/1078-0432 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
discusses	http://id.nlm.nih.gov/mesh/M0444984 http://id.nlm.nih.gov/mesh/M0593322 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006258Q000188 http://id.nlm.nih.gov/mesh/D012878Q000188 http://id.nlm.nih.gov/mesh/D011799Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D002294Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000077156 http://id.nlm.nih.gov/mesh/D002294Q000401 http://id.nlm.nih.gov/mesh/D066246Q000235 http://id.nlm.nih.gov/mesh/D012878Q000401 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006258Q000401 http://id.nlm.nih.gov/mesh/D011799Q000009 http://id.nlm.nih.gov/mesh/D020360 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D066246Q000037 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D060828 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7172 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6651 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629

Showing number of triples: 1 to 69 of 69.